Driven by excellence, focused on strategies for the longer term.

This is the crux of who we are. It is an articulation of precision in purpose, from the Firm’s beginnings to where we are today. Our collective eye is unerringly trained on tomorrow.

Deep sectoral expertise across services and industries.

Our insistence on strategic advisory exacts an in-depth understanding of and involvement with our clients’ businesses and industries. We engage not just individual businesses, but also contribute to the country’s legal and regulatory frameworks.

Personal commitment supported by experience and grit.

We commit early. We pull together internally for greater support. Every effort is sincere, every individual deeply dedicated to their task, their role, to the Firm.

Our undertakings for long-term impact are an organic extension of our purpose.

They are to employ our deep knowledge of the law beyond the business, the transaction, the deal. To use the opportunities and skills we possess, to reflect on the culture we’re creating. Individually and collectively, these are our efforts to help shape the thinking of our future generations, and arm them with strategies for true, sustainable growth.

Knowledge-sharing is intrinsic to equity and inclusivity.

This is a repository of thought leadership, deep insights and strong viewpoints, legal and other news and events and how they impact the industry and our clients.

Relevance is critical to growth. It necessitates a firm that is dynamic and responsive.

Amplifying intrinsic talent, sharpening skills, expanding knowledge, is vital to leading. It defines every aspect of how our firm functions and transacts. This is how we create new benchmarks and set industry standards.

  • Connect
Jul 16, 2024

the investor selling shareholder, BC Investments IV Limited (an affiliate of Bain Capital), on the successful initial public offering by Emcure Pharmaceuticals Limited.

AZB & Partners recently advised the investor selling shareholder, BC Investments IV Limited (an affiliate of Bain Capital), on the successful initial public offering by Emcure Pharmaceuticals Limited, comprising fresh issuance and offer for sale of equity shares for an amount aggregating to INR 19,520 million.

The book running lead managers to the IPO were Kotak Mahindra Capital Company Limited, Axis Capital Limited, Jefferies India Private Limited and J.P. Morgan India Private Limited.

The AZB team comprised our Senior Partner, Agnik Bhattacharyya; our Senior Associates, Kairav Parikh and Aratrika Choudhuri; and our Associates, Harsh Vardhan Singh and Yagnesh Sharma.

AUTHORS & CONTRIBUTORS

  • Partner:

    Agnik Bhattacharyya

  • Associates:

    Kairav Parikh

    Aratrika Choudhuri

    Harsh Vardhan Singh

    Yagnesh Sharma

TAGS

SHARE

Subscribe

DISCLAIMER

These are the views and opinions of the author(s) and do not necessarily reflect the views of the Firm. This article is intended for general information only and does not constitute legal or other advice and you acknowledge that there is no relationship (implied, legal or fiduciary) between you and the author/AZB. AZB does not claim that the article's content or information is accurate, correct or complete, and disclaims all liability for any loss or damage caused through error or omission.

RELATED READING

Deals

Mitsui on their acquisition of a strategic stake in SATS Food Solutions India.

Jun 29, 2025 | Corporate / Mergers & Acquisitions
Deals

Axio (Capital Float) and its founders on Amazon’s ongoing acquisition of Axio.

Jan 23, 2025 | Corporate / Mergers & Acquisitions
Deals

Capital on the acquisition of a significant minority stake in Dhoot Transmission Private Limited.

Jan 22, 2025 | Corporate / Mergers & Acquisitions